MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML). Mediterr J Hematol Infect Dis 2013, 6 (1), e2014009. https://doi.org/10.4084/mjhid.2014.009.